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ABSTRACT: Background: Although smoking is known to be powerful risk factor for other 
vascular diseases, such as cardiac and peripheral vascular disease, only relatively recently 
has evidence for the role of smoking in the development of stroke been established. The 
reasons for this advance lie in the acknowledgement that stroke is a heterogeneous disease, 
in which its subtypes are associated with different risk factors. Furthermore, improvements 
in the stringency of epidemiological studies and the greater use of CT scanning have enabled 
the role of smoking in the development of stroke to be elucidated. Summary of review: This 
is a qualitative examination of high quality epidemiological studies in which the role of 
smoking and passive smoking, as a risk factor for cerebral infarction, intracerebral haemor-
rhage and subarachnoid haemorrhage, is examined. In addition, the pathological mecha-
nisms by which smoking or passive smoking may contribute to the development of stroke 
are reviewed. Conclusion: Smoking is a crucial independent determinant of cerebral infarc-
tion and subarachnoid haemorrhage, however its role in intracerebral haemorrhage is un-
clear. Although studies are limited, there is evidence that exposure to passive smoking may 
also increase the risk of stroke. Smoking appears to be involved in the pathogenesis of 
stroke via direct injury to the vasculature and also by altering haemodynamic factors within 
the circulation. Importantly, smoking is modifiable risk factor for stroke. Therefore, the en-
couragement of smoking cessation may result in a substantial reduction in the incidence of 
this devastating disease.  
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INTRODUCTION 
Although smoking is an established and potent 
risk factor for other vascular diseases, such as cardiac 
and peripheral vascular disease [1,2], the evidence for 
its status as a risk factor for stroke has been gained only 
in the last 20 years [3-33]. That it took so long to estab-
lish smoking as a risk factor for stroke might be largely 
attributed to three main factors. First, epidemiological 
studies have become more stringent over the past two 
decades, with methodology being refined to reduce bias 
associated with ascertainment of both cases and con-
trols. Second, the purpose of many of the earlier studies 
was not to determine whether smoking was a risk factor 
for stroke, but was mainly a result of post-hoc analyses. 
Consequently the methodology was more likely to in-
clude means of inadvertently choosing inappropriate 
samples for comparison. Finally, stroke is a heteroge-
neous condition, and it is only since the introduction of 
CT scanning that an accurate diagnosis of stroke and its 
subtypes has been possible. Previously, it is possible the 
epidemiological studies included other non-stroke con-
ditions that may have been of nonvascular origin. 
Moreover, it is also possible that the differing aetiolo-
gies of cerebral ischaemia and cerebral haemorrhage 
may have resulted in a diminution of risk when these 
stroke subtypes were combined into an overall “stroke” 
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association between smoking and its subtypes (cerebral 
infarction, subarachnoid and cerebral haemorrhage) 
separately. In addition, the studies that will be discussed 
are those that have a high rate of CT for accurate classi-
fication of these subtypes. This review is intended as a 
qualitative overview of the key literature regarding the 
association between smoking and stroke, and is not a 
detailed meta-analysis. 
 
CEREBRAL INFARCTION 
Cerebral infarction is the most common subtype 
of stroke, accounting for more than 70% of all strokes 
[34]. Over the past few decades cigarette smoking has 
been established as a major risk factor for the develop-
ment of cerebral infarction [11-13,17-19,21,23,25,28, 
35]. In a meta-analysis of 22 studies of the association 
between cigarette smoking and stroke prior to 1988, 
Shinton and Beevers found that the relative risk for 
cerebral infarction associated with smoking was 1.92 
(95% CI, 1.71-2.16) [28]. 
The relationship between smoking and cerebral 
infarction has been confirmed in more recent case-
control studies from the U.S., Australia, U.K., Scandi-
navia, and Russia (Table 1) [10-13,17,20,23,25,35]. In a 
study among more than 400 patients in Australia, Don-
nan and colleagues found that the risk of cerebral in-
farction due to smoking was substantially higher than in 
the previous meta-analysis [10]. In this study, which 
included adjustments for the potentially confounding 
effects of hypertension, high cholesterol, previous myo-
cardial infarction, alcohol consumption and oral contra-
ceptive use, the relative risk of cerebral ischaemia asso-
ciated with current smoking was 3.6 (95% CI, 2.5-5.9). 
Similar results were found by Gorelick and colleagues 
in the United States and by Gill and colleagues in the 
United Kingdom [12,13]. In the latter case-control 
study, which included 368 cases of CI and 573 controls, 
the adjusted relative risk of CI with smoking was 3.19 
(95% CI, 1.8-5.5) among men and 2.3 (95% CI, 1.2-
4.2) among women after adjustment for confounding 
variables such as age, social class, hypertension and 
alcohol consumption.  
Similar results have been obtained in cohort stud-
ies in the United States and Taiwan [18,19,21,36]. In 
the U.S. Physicians’ Health Study, Kurth and col-
leagues found that current smoking was associated with 
a twofold increase in the risk of ischaemic stroke (RR 
2.11, 95% CI, 1.72-2.60) [19]. Those smoking <20 
cigarettes/day were found to have a 1.6-fold increase in 
the risk of ischaemic stroke (RR, 1.56, 95% CI, 1.03-
2.37) and this increased to 2.25 (95% CI, 1.80-2.81) 
among those smoking ≥20 cigarettes/day when com-
pared to never smokers. These relative risks were ad-
justed for the confounding effects of age, alcohol con-
sumption, exercise and parental history of myocardial 
infarction less than 60 years of age. In a similar study 
conducted in a large cohort of female nurses, Kawachi 
and colleagues found that current smokers were at a 
significantly greater risk of CI (RR 2.53, 95% CI, 1.91-
3.35) [18]. Importantly, these investigators found a 
dose-response relationship between the level of smok-
ing and cerebral infarction (p = 0.03). Those smoking 
1-14 cigarettes/day had an adjusted RR of 1.8 (95% CI, 
1.04-3.23), with the risk increasing to 3.97 (95% CI, 
2.09-7.53) for women smoking ≥35 cigarettes/day., 
Together, these studies provide evidence that smoking 
increases the risk of cerebral infarction in both men 
and women, with the risk being greater in those who 
smoke more. 
The use of pack-years by investigators to deter-
mine the dose of lifetime exposure to cigarettes was 
used in some studies [13,23]. This is a combination of 
both the number of cigarettes smoked per day and the 
duration of smoking (where a pack is defined as 20 
cigarettes per day and this is multiplied by the number 
of years to calculate pack-years). Love and colleagues 
reported that the risk of cerebral infarction increased by 
4% per pack-year smoked. In support of these findings, 
Gorelick and colleagues found that individuals who had 
been smoking for 1-33 pack-years had an odds ratio 
(OR) for cerebral infarction of 2.48 (95% CI, 1.43-
4.29). This increased to an OR of 5.60 (95% CI, 3.17-
9.88) in those smoking more than 33 pack-years. This 
provides evidence that there is an increased stroke risk 
with increased pack-years of smoking. 
The difference in the definition used for exposure 
is an important issue. Measuring pack-years provides 
information on both the quantity of cigarettes smoked 
and the duration of this level of smoking. Thus it could 
be that either or both of these factors contribute to the 
increased stroke risk. It would be useful to determine 
whether one pack per day for 20 years produced a 
stroke risk similar to that of two packs per day for 10 
years (with both equating to 20 pack-years). However, 
this type of information relies heavily on participant 
recall. Such accurate recall may be challenging, espe-
cially for individuals with cognitive deficits following 
stroke. Partly because of the difficulties outlined, it 
remains to be established whether it is the quantity or
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 No.  CI 
cases 
(No. in 
cohort) 
No. 
Controls 
Smoking 
Status 
RR/ 
OR 
95% CI  Adjustments†  Matching 
Case-Control 
Studies 
        
Donnan et al. [10] 
Melbourne, Aus-
tralia, 1989 
422 422  Never  smoker 
Ex smoker 
Current smoker 
1.0 
2.0 
3.6 
 
1.3-3.2 
2.2-5.9 
Hypertension, High 
cholesterol, MI, alcohol 
consumption, oral 
contraceptive use. 
Age, sex, 
neighbourhood 
Gorelick et al [13] 
Illinois, U.S. 1989 
205 410  0  (pack-years) 
1-32 (pack years) 
≥33 (pack-years) 
1.00  
2.48  
5.60 
 
1.43-4.29 
3.17-9.88 
Hypertension, and 
alcohol consumption.  
Age, race, sex 
and method of 
hospital payment
Gill et al [12] 
British Midlands, 
U.K 1989 
368 573  Nonsmokers 
Current (Male) 
Current (Female) 
1.00 
3.19  
2.26 
 
1.8-5.5 
1.2-4.2 
Age, race, social class, 
alcohol consumption 
and treatment of hyper-
tension. 
Love et al. [23] 
Iowa, U.S.  
1990 
181 
15-45 
years 
 
307 Current  Smoker 
Past Smoker 
Per cigarette/day 
Per pack-year 
1.43  
0.64  
1.01  
1.04 
0.98-2.11 
0.25-1.69 
1.00-1.03 
1.02-1.05 
No adjustments.  Age, gender, 
hospital admis-
sion date, and 
county of resi-
dence. 
Ellekjær et al [35] 
North Trøndelag 
County, Norway 
1992. 
163 567  Never  smoker 
Current Smoking 
Prior Smoking 
1.00 
1.72  
2.54 
 
0.85-3.51 
1.22-5.29 
Diabetes, previous 
myocardial infarction, 
previous stroke, and 
systolic blood pressure. 
Sex, year of 
birth, and local 
government 
area. 
Lidegaard et al. 
[20] 
Denmark, 1993 
320 
females 
15-44 
years 
1198 Never  smoker 
Former smoker 
Smoking ≤10/day 
Smoking >10/day 
1.0 
0.6 
1.6  
1.5 
 
0.4-0.9 
1.1-2.4 
1.1-2.0 
Age, use of oral 
contraceptives, years 
of schooling 
 
Jamrozik et al. 
[17] 
Perth, Australia, 
1994 
360 518  Never  Smoker 
Ex-smoker 
Current (1-20/day) 
Current (≥21/day) 
1.00  
0.49  
1.45  
4.92 
 
0.31-0.81 
0.81-2.68 
1.90-12.7 
Alcohol, hypertension, 
diabetes, previous stroke 
or TIA, previous MI, 
adding salt to food, fish 
consumption > 2 per 
month.  
Sex and age. 
Petitti et al [25] 
California, US 
1996 
144 
females 
15-44 
years 
774 Never 
Past 
Occasional 
Current 
1.00  
0.94  
1.38  
2.66 
 
0.55-1.59 
0.42-4.56 
1.65-4.30 
No adjustments.  Year of birth, 
location of 
facility. 
Feigin et al [11] 
Novosibirsk, 
Russia 1998 
237 237  Non  smoker 
Current 
1.00  
2.20 
 
0.99-4.78 
Hypertension, LVH, 
IHD, mitral valve 
disease, and BMI. 
Age and sex. 
Continued on Page 70
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the duration of smoking that results in the increased risk 
of cerebral infarction.  
The effect of cessation of smoking on the subse-
quent development of cerebral infarction is important in 
determining a causal relationship between this disease 
and smoking. In men, Kurth and colleages found that 
past smokers had a risk of cerebral infarction compara-
ble to that of never smokers (RR 0.99, 95% CI, 0.86-
1.14) [19]. Kawachi and colleagues provided further 
evidence for a return to never smoking risk levels 
among those who cease smoking [18]. They examined 
the number of years since quitting smoking (<2 years, 
2-4 years, 5-9 years, 10-14 year and >15 years) on the 
risk of cerebral infarction in women. Current smokers 
were used as reference for the reduction in risk. At two 
years after quitting, the risk of stroke was reduced by 
46% (RR 0.54, 95% CI, 0.26-1.55). This equated to 
80% of the benefit of smoking cessation and demon-
strating the immediate benefits of smoking cessation. 
Furthermore, the relative risk of ischaemic stroke 
among former smokers returned to the level of never 
smokers during the interval between 2 and 4 years fol-
lowing smoking cessation.  
Similar results have been reported from case-
control studies. In studies conducted in the U.S. 
[23,25], ex-smokers were found to have a risk of cere-
bral infarction similar to that of never smokers (RR 
0.94, 95% CI, 0.55-1.59) and (0.64 95% CI, 0.25-1.69) 
for each of these studies respectively. Although it is 
possible that ex-smokers may reduce their risk of cere-
bral infarction simply by ceasing smoking, other life-
style changes made at the time of smoking cessation 
may contribute to a reduction in cerebral infarction risk.  
 
SUBARACHNOID HAEMORRHAGE 
Subarachnoid haemorrhage (SAH) accounts for 
only about 2-9% of strokes [37], but is associated with 
mortality of between 39% and 58% at one year and
Table 1, Continued 
 No.  CI 
cases 
(No. in 
cohort) 
No. 
Controls 
Smoking Status RR/ 
OR
95% CI  Adjustments†  Matching 
Cohort Studies           
Kawachi et al 
[18] 
Nurses’ Health 
Study, U.S., 
1993. 
275 
(117006 
females) 
Rest of 
stroke free 
cohort 
Never Smokers 
Ex-smokers 
Current Smokers 
1-14/day 
15-24/day 
25-34/day 
≥35/day 
1.00 
1.27  
2.53  
1.83  
3.57  
2.73  
3.97 
 
0.85-1.89 
1.91-3.35 
1.04-3.23 
2.36-5.42 
1.49-5.03 
2.09-7.53 
Age, hypertension, 
diabetes, BMI, high 
cholesterol, oral contra-
ceptive use, HRT, age of 
smoking commencement, 
and follow-up period. 
 
Benfante et al. 
[36] 
Hawaii, 1994 
226 5567  (rest 
of cohort) 
Non smokers 
Current Smokers 
1.0 
2.30 
 
1.8-3.0 
 
Lee et al. [21] 
Taiwan, 1995 
115 
(2600, > 
65 years) 
Rest of 
Cohort 
Never smokers 
Current Heavy (> 
20 per day) 
1.00 
1.72 
 
1.00-2.96 
Age, sex, hyperten-
sion, diabetes, and 
alcohol. 
Prevalence 
Study 
Kurth et al. [19] 
Physicians’ 
Health Study, 
US, 2003 
913 
(22022 
Males) 
Rest of 
cohort 
Never Smokers 
Ex-Smokers 
Current Smokers 
<20/day 
≥20/day 
1.00  
0.99  
 
1.56  
2.25 
 
0.86-1.14 
 
1.03-2.37 
1.80-2.81 
Age, alcohol, exercise, 
parental history of MI 
<60 yr, and randomised 
treatment group. 
 
CI, cerebral infarction; RR, relative risk; OR, odds ratio; 95% CI, Confidence Interval; †adjustments refer to adjust-
ments made in multivariate analyses. MI, myocardial infarction; TIA, transient ischaemic attack; LVH, left ventricular 
hypertrophy; IHD, ischaemic heart disease; BMI, body mass index; HRT, hormone replacement therapy. 
70     Paul SL, Thrift AG, Donnan GA significant morbidity [34,38]. This form of stroke tends 
to occur at younger ages than other forms of stroke 
[34]. The contribution of cigarette smoking to this dev-
astating disease has been reported by numerous investi-
gators [6,12,16,18,19,26,28]. In a meta-analysis of 10 
studies of the association between smoking and SAH, 
the relative risk of SAH among current smokers was 
2.93 (95% CI, 2.48-3.46) [28]. More recently, Kurth 
and colleagues found that among current smokers the 
age-adjusted RR for SAH was 3.61 (95% CI 1.54-8.50; 
Table 2) [19]. This study involved more than 22,000 
male physicians and included 31 cases of SAH [16]. 
The work of Qureshi and colleagues, which included 
323 patients with SAH, adds further support for these 
findings [26]. On examination of the medical records of 
those with SAH admitted to John Hopkins Medical 
Center between 1990 and 1997, an analysis of risk fac-
tors was performed using community-based controls 
matched for age, sex and ethnicity. More patients with 
SAH (46%) were smokers than controls (29%), provid-
ing an adjusted odds ratio (OR) of 5.2 (95% CI, 3.6-7.5) 
for current smokers.  
Table 2: Smoking and the risk of subarachnoid haemorrhage: summary of studies 
 No. 
SAH 
cases 
(No.  in 
cohort) 
No.  of 
con-
trols 
Smoking 
Status 
RR/
OR 
95% CI  Adjustments†  Matching 
Case-Control Studies        
Gill et al. [12] 
British Midlands, 
UK, 1989 
208 573  Nonsmoker 
Current (Male) 
Current (Female) 
1.00  
4.52  
2.52 
 
2.4-8.4 
1.4-4.5 
Age, race, social class, 
alcohol consumption and 
treatment for hyperten-
sion 
 
Quereshi et al. 
[26] 
Maryland US, 
2001 
323 969  Never 
Current Smoker 
Previous Smoker 
1.0  
5.2  
4.5 
 
3.6-7.5 
3.1-6.5 
Hypertension, diabetes, 
alcohol consumption.  
Age, 
sex, and 
ethnicity. 
Isaksen et al. 
[16] 
Tromsø County, 
Norway, 2002 
26 104  Never 
Former 
Current 
1.00  
2.13  
4.55 
 
1.04-4.39 
1.08-19.30 
Systolic and diastolic 
blood pressure, serum 
cholesterol, serum HDL, 
BMI, coffee consump-
tion.  
Age and sex.
Cohort Studies            
Kawachi et al. 
[18] 
Nurses’ Health 
Study, U.S. 1993 
108 
(117006 
females) 
Rest of 
Cohort 
Never Smokers 
Past Smokers 
Current Smokers 
1-14/day 
15-24/day 
25-34/day 
≥35/day 
1.00  
2.26  
4.85  
4.28  
4.02  
7.95  
10.22 
 
1.16-4.42 
2.90-8.11 
1.88-9.77 
1.90-8.54 
3.50-18.07 
4.03-25.94 
Age, hypertension, 
diabetes, BMI, high 
cholesterol, oral contra-
ceptive use, HRT, age of 
smoking commencement, 
and follow-up period. 
 
Kurth et al. [19] 
U.S. Physicians’ 
Health Study 
2003 
31 
(22022 
males) 
Rest of 
Cohort 
Never Smokers 
Ex-Smokers 
Current (<20/day) 
Current (≥20/day 
1.00  
0.79  
1.75  
3.22 
 
0.37-1.68 
0.24-13.09 
1.26-8.18 
Age, sex, and randomised  
treatment group 
 
SAH, subarachnoid haemorrhage; RR, relative risk; OR, odds ratio; CI, 95% Confidence Interval; †adjustments, refers 
to adjustments made for either univariate or multivariate analysis. HDL, high density lipoprotein; BMI, body mass index; 
HRT, hormone replacement therapy. 
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an adjusted relative risk of SAH of 4.85 (95% CI, 2.90–
8.11) among current women smokers [18]. Importantly, 
these investigators also found that those smoking 1-14 
cigarettes/day had an adjusted relative risk (RR) of 
SAH of 4.28 (95% CI, 1.88–9.77), which increased to 
10.22 (95% CI, 4.03–25.94) in those smoking ≥35 ciga-
rettes/day. They further reported a dose-response rela-
tionship between the daily number of cigarettes smoked 
and SAH (p < 0.0004). This provides evidence for a 
causal association between smoking and SAH. 
The RR of SAH among former smokers is consis-
tently less than that among current smokers [16,18,19, 
26]. In the Nurses’ Health Study, women who ceased 
smoking were at less risk of SAH than those who con-
tinued to smoke, with RRs of 2.01 (95% CI, 1.12-3.61) 
and 4.96 (95% CI 3.13-7.87) respectively [18]. The 
investigators also reported that the RR of SAH among 
former smokers returned to the level of never smokers 
during the interval between 5 and 9 years following 
smoking cessation. 
These studies demonstrate that smoking is a ma-
jor independent risk factor for SAH. Importantly, this 
association is strengthened by the presence of a dose-
response relationship. Of note is that ex-smokers are 
found to be at a higher risk of SAH than never smokers 
for many years after smoking cessation, but it appears 
that within 10 years their risk will return to that of a 
never smoker [18].  
 
INTRACEREBRAL HAEMORRHAGE 
In a meta-analysis of published studies of smok-
ing and intracerebral haemorrhage (ICH), the pooled 
relative risk of ICH associated with smoking was 
0.74 (95% CI, 0.56-0.98) [28]. However, the authors 
acknowledged that this result was heavily influenced 
by a single study conducted in neurological hospitals. 
There have been conflicting reports of the role of smok-
ing in the development of ICH. Some investigators 
have reported that heavy smoking is associated with 
ICH [17,19], while others have reported no association 
between smoking and ICH (Table 3) [12,24,39].  
The most recent published data on smoking and 
intracerebral haemorrhage comes from the Physicians’ 
Health Study, which included 108 cases of ICH [19]. 
The investigators found that the RR for ICH among 
current smokers was 1.98 (95% CI 1.07-3.65) when 
compared to never smokers. This RR was adjusted for 
age, alcohol consumption, exercise, parental history of 
myocardial infarction under 60 years and randomised 
antioxidant treatment. A non-significant dose-response 
trend was noted with those smoking <20 cigarettes/day 
having a 1.6-fold increase (RR 1.6, 95% CI, .50-5.07) 
in the risk of intracerebral haemorrhage, with the risk 
increasing to a 2.1-fold increase (RR 2.06, 95% CI, 
1.08-3.96) in those smoking ≥20 cigarettes/day. 
Another study that somewhat supports the find-
ings of Kurth and colleagues involved a prospective 
study of haemorrhagic stroke patients in the US [40]. 
Although the investigators found smoking was not an 
independent risk factor for haemorrhagic strokes overall 
(OR 1.3, 95% CI, 0.8-2.0), this finding was limited by 
those with non-lobar haemorrhage [40]. In contrast the 
association between smoking and lobar haemorrhages 
was more than twofold (OR 2.4, 95% CI, 1.1-5.2).  
In contrast to the previously mentioned findings, 
numerous investigators have found no association be-
tween smoking and ICH. In a large sample of patients 
with ICH (331) and using case-control methodology, 
Thrift and colleagues found no increased risk of in-
tracerebral haemorrhage associated with smoking (ad-
justed OR, 1.07, 95% CI, 0.63-1.81) [39]. Importantly, 
the cases and controls in this study were matched for 
age (±5 years), sex, and neighborhood of residence (the 
latter allowing some degree of matching for socioeco-
nomic status). In addition, the potentially confounding 
effects of hypertension, cholesterol, body mass index, 
previous cardiovascular disease, exercise, education 
level, diabetes, and alcohol consumption were adjusted 
for in the analyses. 
The results of 13 studies, in which the contribu-
tion of smoking in the risk of ICH was investigated, 
were included in a recent meta-analysis [41]. The au-
thors found that the risk of ICH with smoking was 1.31 
(95% CI, 1.09-1.50). However, this study was limited 
by the fact that no adjustments could be made by poten-
tially confounding factors, and so the independence of 
smoking as a risk factor could not be established. 
Therefore, the contribution of smoking to the risk of 
ICH is still in doubt. 
 
PASSIVE SMOKING AND THE RISK 
OF STROKE 
Beyond the damage that active smoking may 
cause an individual are the adverse effects that inhaling 
environmental tobacco smoke (ETS) from the sidestream 
smoke of a burning cigarette may cause others. This 
smoke contains high concentrations of CO, nicotine and 
carcinogens [42]. In some cases these combustion 
products are of a higher concentration in sidestream
72     Paul SL, Thrift AG, Donnan GA Table 3: Smoking and the risk of intracerebral haemorrhage: summary of studies
 No. 
ICH 
cases 
(No. in 
cohort) 
No. 
controls 
Smoking Status RR/OR 95% CI  Adjustments†  Matching 
Case-Control 
Studies 
          
Gill et al. [12] 
British Midlands, 
UK, 1989 
104 573  Non  Smokers 
Current (Male) 
Current (Female) 
1.00 
1.82 
1.30  
 
0.9-3.7 
0.5-3.4 
Age, race, social class, 
alcohol consumption, and 
treatment of hypertension. 
 
Monforte et al. 
[24] 
Barcelona, Spain, 
1990 
24 48    Non-smokers 
Current smokers 
1.00 
1.52  
 
0.41-5.57 
No adjustments.   Age and sex. 
Jamrozik et al. 
[17] 
Perth, Australia, 
1994 
59 279  Never  Smoker 
Ex-smoker 
Current (1-20/day) 
Current (≥21/day) 
1.00  
1.11  
3.17  
9.84  
 
0.43-2.85 
0.92-11.0 
2.09-46.4 
Alcohol consumption, 
history of hypertension, 
diabetes, previous stroke 
or TIA, previous MI, add-
ing salt to food, fish con-
sumption > 2 per month.  
Sex and age. 
Thrift et al.[39] 
Melbourne, Aus-
tralia, 1999 
331 331  Never 
Smokers 
Ever Smokers 
Current Smoker 
Previous Smoker 
1.00 
0.96  
1.07  
0.89 
 
0.63-1.45 
0.63-1.81 
0.56-1.42 
Hypertension, cholesterol, 
BMI, previous cardiovas-
cular disease, exercise, 
education level, diabetes, 
and alcohol. 
Age, sex, and 
neighbourhood. 
Woo et al. [40] 
Cincinatti, US, 
2002 
188 sur-
vivors 
368 Non-smokers 
Current Smokers 
Current Smokers 
Current Smokers 
1.0 
1.3 
2.4 
0.9 
 
0.8-2.0 
1.1-5.2 
0.5-1.6 
No adjustments 
All ICH 
Lobar ICH 
Non-Lobar ICH 
 
Cohort Studies            
Kawachi et al. 
[18] 
Nurses’ Health 
Study, US, 1993 
53 
(117006 
Females) 
Rest of 
Cohort 
Never Smokers 
Past Smokers 
Current Smokers 
1-14/day 
15-24/day 
≥ 25/day 
1.00  
1.24  
1.24  
1.68  
2.53  
1.41 
 
0.64-2.42 
0.64-2.42 
0.34-5.28 
0.71-6.05 
0.39-5.05 
Age, hypertension, diabe-
tes, BMI, high cholesterol, 
oral contraceptive use, 
HRT, age of smoking 
commencement, and fol-
low-up period. 
 
Kurth et al. [19] 
US Physicians’ 
Health Study, 
2003 
108 
(22022 
Males) 
Rest of 
Cohort 
Never Smokers 
Past Smokers 
Current 
(<20/day) 
Current (≥ 
20/day) 
1.00  
0.80 
1.60  
2.06 
 
0.54-1.20 
0.50-5.07 
1.08-3.96 
Age, exercise, parental 
history of MI before age 
60, alcohol consump-
tion, and randomized 
treatment group 
 
ICH, intracerebral haemorrhage; RR, relative risk; OR, odds ratio; 95% CI, 95% Confidence Interval; †adjustments, 
refers to adjustments made for either univariate or multivariate analysis. TIA, transient ischaemic attack; MI, myocar-
dial infarction; BMI, body mass index; HRT, hormone replacement therapy. 
A Review of Smoking and Stroke     73smoke than in the mainstream smoke inhaled by the 
smoker [42]. As many investigations have been made 
into the role of active smoking in the development of 
stroke, it is interesting to find that only a small number 
of studies have been focused on the role of ETS in the 
pathogenesis of stroke. 
The first examination of the link between expo-
sure to ETS and the development of stroke was con-
ducted by Lee and colleagues using a hospital based 
case-control study [43]. The study included non-
smokers whose spouses were current smokers with lung 
cancer. The non-smoking spouses (n=55) were then 
matched to controls with non-smoking spouses 
(n=254). No significant increase in the risk of stroke 
was found among smokers’ spouses (RR 0.90, 95% CI, 
0.53-1.52) when compared to non-smokers’ spouses. In 
contrast to these findings, in a case-control study in-
volving 452 cases, You and colleagues reported a bor-
derline association between ischaemic stroke and expo-
sure to ETS via a spouse in non-smokers (OR 1.70, 
95% CI, 0.98–2.92) [33]. 
The most recent study on passive smoking and 
stroke was a population based case-control study con-
ducted in New Zealand [8]. The study involved 521 
cases of first ever stroke and 1,800 community-based 
controls. The authors defined passive smokers as those 
exposed to smoking via a household member who regu-
larly smoked in their presence or a co-worker who 
smoked indoors in their presence for more than one of 
the past 10 years. After adjusting for potentially con-
founding factors such as sex, hypertension and diabetes, 
the odds ratio of developing stroke associated with ex-
posure to ETS was 1.82 (95% CI, 1.34-2.49). This pro-
vides some evidence that non-smokers who are exposed 
to ETS have a greater risk of developing stroke than 
those not exposed to ETS.  
In support of these findings, potential mecha-
nisms whereby ETS may contribute to the pathogenesis 
of stroke have been identified. The Atherosclerosis Risk 
in Communities (ARIC) study investigators presented 
findings linking ETS to the development of carotid 
atherosclerosis [44]. After controlling for demographic, 
life-style and other risk factors, intimal-medial thicken-
ing was found to be greater in non-smokers who were 
exposed to ETS, than non-smokers who were not ex-
posed to ETS. In addition, the rate of progression of 
intimal-medial thickening was significantly greater 
among non-smokers exposed to ETS (p=0.003). Fur-
thermore, Kiechl and colleagues found non-smokers 
exposed to ETS had a greater risk of developing early 
(OR 1.3, 95% CI, 1.0-1.8) and advanced atherosclerosis 
(OR 1.5, 95% CI, 1.0-2.2) than non-smokers not ex-
posed to ETS [45]. 
Overall, data from the few studies conducted on 
exposure to ETS and the development of stroke, to-
gether with data concerning ETS and atherosclerosis, 
provide some support for the notion that ETS can lead 
to the development of stroke. To clarify the role of ETS 
in the development of stroke, studies must be designed 
to determine whether altering the amount or duration of 
ETS changes the rate of stroke within a population. 
More evidence is needed on the role of ETS in the 
development of stroke. An examination of the effect of 
ETS by stroke subtype may better evaluate the relation-
ship between this potentially modifiable risk factor and 
stroke.  
 
CIGARETTE SMOKING IN THE 
PATHOGENESIS OF STROKE 
Smoking appears to be involved in the patho-
genesis of stroke via two mechanisms. First, smoking 
can cause direct damage to the vasculature, altering 
both its architecture and function [44-54]. Second, 
smoking has effects on haemodynamic factors within 
the circulation [53, 55-64]. By discussing the implica-
tions of these alterations in function by stroke aetiol-
ogy, the role of smoking in the pathogenesis of stroke is 
better elucidated. Two distinct types of stroke will be 
discussed, cerebral infarction and haemorrhagic stroke 
(including ICH and SAH). 
 
Smoking and the development 
of cerebral infarction  
Cerebral infarction occurs due to a disruption of 
the blood supply to the cerebral arteries. This can be a 
consequence of either occlusion of the cerebral vessels 
themselves or due to occlusion of the carotid arteries. 
There are a number of ways in which this occlusion can 
occur including artery occlusion by atherosclerosis and 
its associated plaques and thrombi or via emboli from a 
ruptured atherosclerotic plaque.  
Smoking is a major factor in the development of 
atherosclerosis. In the ARIC study current smokers 
were found to have the greatest progression of athero-
sclerosis over time, at a rate 50% greater than in non-
smokers [44]. Furthermore, it was found that ETS ex-
posure was associated with an approximately 20% 
greater rate of atherosclerosis progression than for non-
smokers not exposed to ETS. Similar findings have 
been reported by others [48]. 
Smoking is believed to induce the development of 
atherosclerosis by initiating endothelial injury, presum-
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via direct toxic effects of cigarette smoke constituents. 
Even brief exposure to cigarette smoke has been found 
to activate leukocytes, stimulating the release of the 
pro-coagulant, von Willebrand Factor (vWF) and caus-
ing endothelial damage [56]. This initiates a cascade of 
inflammatory mechanisms that result in atherosclerosis. 
The mechanisms by which endothelial dysfunc-
tion and a reduction in dilatory ability occur were fur-
ther investigated by Fang and colleagues in the cerebral 
arteries of rats [49]. They reported that nicotine infu-
sion reduced the dilatory ability of pial vessels to nitric 
oxide synthase (NOS) dependant agonists. In addition, 
this response was inhibited by administration of super-
oxide dismutase. These findings provide evidence that 
nicotine has its effects via the formation of oxygen radi-
cals. The authors speculated that this oxygen radical 
induced impairment of dilation is important in the oc-
currence of vascular dysfunction after exposure to ciga-
rette smoke. 
Studies on arteries of human smokers have found 
similar results to Fang and colleagues. Poredôs and 
colleagues reported data on the intima-media thickness 
(IMT) of smokers compared with non-smokers, with 
IMT being used as a measure of atherosclerotic change 
[65]. The investigators found that those who smoked 
had a significantly greater IMT than non-smokers. In 
addition, Celermajer and colleagues demonstrated that 
the arteries of smokers had diminished or absent flow-
mediated dilation, giving evidence of endothelial dys-
function [66].  
The ramifications of the reduction in dilatory 
ability following smoking may place smoking individu-
als at a higher risk of cerebral ischaemic events in two 
ways. First, due to both a reduced ability to respond to 
alteration in perfusion pressure, and second, due to lack 
of distensibility of the arterial wall as a result of endo-
thelial dysfunction. The notion that this lack of disten-
sibility of the arterial wall may increase the risk of 
atherosclerotic plaque rupture, leading to emboli and 
subsequent infarction, was presented by Kool and col-
leagues [52]. They found that blood pressure and heart 
rate were significantly increased following smoking, 
whereas carotid artery distensibility was significantly 
decreased. It was postulated that the increased wall 
stiffness, blood pressure and heart rate could cause an 
increase in load on the vessel wall, which could lead to 
plaque rupture and acute ischaemic events. This is par-
ticularly relevant in light of evidence that smokers have 
increased levels of atherosclerosis. 
Studies conducted on the reactivity of the cerebral 
vessels of smokers are particularly pertinent to the role 
of smoking in the development of stroke. Terborg and 
colleagues investigated the reactivity of the cerebral 
circulation in smokers to hypercapnia using near-
infrared spectroscopy and transcranial Doppler sono-
graphy [67]. It was found that at rest smokers have 
normal autoregulatory ability, yet immediately after 
smoking their vasomotor reactivity to hypercapnia was 
impaired. This was due to a reduced vasodilatory ability 
reflecting endothelial dysfunction. It was suggested that 
these acute reversible effects of cigarette smoking could 
place smokers at an enhanced stroke risk, presumably 
due to the reduced ability of the cerebral circulation to 
response to decreases or disruptions in perfusion pres-
sure in this period immediately following smoking. 
In addition to the atherosclerotic changes that 
cigarette smoking induces in the vessel wall, smoking 
also has detrimental effects on the coagulant/anti-
coagulant balance throughout the vascular system of 
smokers. This imbalance predisposes these individuals 
to thrombosis and therefore an increased risk of cere-
bral infarction. Hioki and colleagues investigated the 
effects of smoking on thrombin generation, which is 
important in the conversion of fibrinogen to fibrin in 
the coagulant cascade [57]. It was evident from their 
findings that even when not smoking, current smokers 
had significantly elevated levels of thrombin. These 
levels were seen to increase further immediately after 
smoking. Examination of serum of smokers also reveals 
that smokers have significantly increased fibrinogen 
and white blood cell counts when compared to non-
smokers [68], giving further credence to the suggestion 
that smokers are more prone to coagulation and throm-
bosis than non-smokers. Investigations on the effect of 
nicotine on haemostatic functions have found that nico-
tine increases the production of the tissue plasminogen 
activator (tPA) inhibitor (plasminogen activator inhibi-
tor-1, PAI-1). The presence of tPA in the circulation is 
important for fibrinolysis. Its inhibition is regulated by 
PAI-1 from both platelet and endothelial sources, which 
binds to fibrin strands causing the inactivation of tPA. 
This ultimately results in a reduction in fibrinolysis and 
therefore thrombus formation. A study exposing human 
brain endothelial cells to nicotine is particularly rele-
vant to the discussion of smoking and stroke. In this 
study Zidovetski and colleagues discovered that the 
administration of nicotine to these cells resulted in an 
increased production of PAI-1 [63].  
Human studies show similar findings, with long-
term smokers shown to have significantly increased 
levels of PAI-1 when compared to non-smokers [61]. In 
A Review of Smoking and Stroke     75addition, the ratio of tPA to PAI-1 was found to be low-
est in smokers, suggesting that smokers have the lowest 
potential for fibrinolytic activity that may lead to a 
greater tendency for thrombus among smokers. The 
authors noted the apparent close association between 
tPA and PAI-1 levels and suggested that there is most 
probably mechanisms ensuring a balance of the activa-
tor and inhibitor. In smokers it would appear that this 
balance is not maintained and this may predispose these 
individuals to pathological conditions such as stroke. 
Investigations into tPA and PAI-1 levels in stroke pa-
tients reveal that patients have significantly elevated 
plasma levels of both tPA and PAI-1, along with in-
creased active PAI-1 [64]. It was also found that there 
was a significant increase in tPA: PAI-1 complexes, 
suggesting that PAI-1 is inhibiting active tPA. This 
provides evidence that patients with stroke may indeed 
have decreased fibrinolytic activity resulting in an 
increased risk of thrombosis and therefore cerebral in-
farction.  
These investigations demonstrate that cigarette 
smoking induces both short-term and long-term altera-
tions in haemodynamic variables, and can also alter 
arterial wall architecture resulting in atherosclerosis. In 
turn these alterations can result in occlusion of vessels 
due to stenosis within the carotid region and emboli 
from a ruptured atherosclerotic plaque, increasing the 
risk of a cerebral infarction. The reduction in the risk of 
cerebral infarction following smoking cessation may be 
due to the resolution of acute pathological changes 
caused by smoking such as alterations in haemodynam-
ics, rather than a reversal of more chronic changes such 
as atherosclerosis. However, this is speculative as the 
effects of smoking cessation on these variables has not 
been investigated. 
  
Smoking and the development 
of haemorrhagic stroke 
The role of smoking in the pathogenesis of haem-
orrhagic stroke has been less investigated. This is sur-
prising given the strong association found between 
smoking and SAH in particular [6,12,16,18,19,26,28]. 
Cerebral haemorrhage occurs due to a rupture of a 
cerebral artery causing an influx of blood into either the 
subarachnoid space (in SAH) or into the brain paren-
chyma (in ICH).  
SAH is known to be due to the rupture of an ar-
tery and in many cases the rupture of a saccular aneu-
rysm [69]. Importantly, it has been found that smokers 
have a greater amount of aneurysms that are also larger 
in size than those in non-smokers [70,71]. ICH is gen-
erally associated with the rupture of small arteries 
within the brain parenchyma. As with cerebral infarc-
tion, it would appear that it is structural damage to the 
arterial wall that leads to the increased risk of haemor-
rhage. Aneurysms and/or rupture of cerebral arteries 
occur due to a weakening of the vessel wall. In the case 
of aneurysm it has been proposed that the degradation 
of elastin within the blood vessel wall may weaken the 
wall, making it susceptible to dilatation at points of 
high flow disturbance such as the branching of arteries 
within the Circle of Willis [70]. This degradation of 
elastin may be due to a reduction of the activity of pro-
tease inhibitors, namely α1 antitrypsin. Smoking is 
known to inactivate α1 antitrypsin via peroxynitrates 
and •OH compounds found within cigarette smoke [50]. 
Furthermore, examination of smokers has found in-
creased elastase degradation products in their urine 
[72]. Tartara and colleagues suggested that a defect in 
α1antitrypsin activity may cause an imbalance between 
proteolytic enzymes and systemic inhibitory capacity; 
in turn there would be an increase in collagen turnover 
resulting in a weakening of the arterial wall [73]. This 
might result in the progression of an aneurysm or also 
rupture of aneurysm, resulting in SAH, or the decreased 
strength of vessel walls could result in intracerebral 
arterial rupture resulting in ICH. In support of this 
hypothesis are data showing that smoking patients with 
SAH have significantly reduced levels of α1 antitrypsin 
[73]. 
The potential implications of these structural al-
terations in the arterial wall of smokers may also lead to 
an increased risk of haemorrhage due to the alteration 
in blood pressure caused by smoking. A sharp rise in 
blood pressure has been observed immediately after 
smoking and can last for up to three hours [22,52]. Ju-
vela and colleagues proposed that these rises in blood 
pressure could contribute to the rupture of aneurysms or 
even small intracerebral arteries [74].  
The data relating to acute changes due to smok-
ing, such as blood pressure surges, teamed with data on 
chronic smoking related changes, such as arterial wall 
degradation, provide a hypothesis for the role of smok-
ing in the development of haemorrhagic stroke. Fur-
thermore, it is evident that the cessation of smoking 
may lower haemorrhagic stroke risk due to the elimina-
tion of acute effects such as blood pressure surges. 
However, the chronic effects of smoking such as arte-
rial wall degradation may remain. This may explain 
why although the risk of haemorrhagic stroke declines 
with smoking cessation, it does not revert to that of an 
individual who has never smoked [16,18,19,26].  
76     Paul SL, Thrift AG, Donnan GA CONCLUSION 
Smoking is an established risk factor for both 
cerebral ischaemia and subarachnoid haemorrhage. 
However, its role in ICH is less clear. There is support-
ing evidence for a causal relationship between smoking 
and CI or SAH. This is supported by reports of a dose-
response relationship between smoking levels and these 
two types of stroke, as well as a return to never smok-
ing risk levels with increased time since quitting smok-
ing. Furthermore, the biological plausibility of these 
findings provides further evidence for the role of smok-
ing in these diseases.  
Establishing smoking as a significant risk factor 
for CI and SAH is important, as this is a modifiable risk 
factor. The evidence that among smokers who cease 
smoking the risk of both of these forms of stroke re-
turns to never smoking levels over time indicates that 
people who cease smoking can benefit in an important 
way. Prevention still remains the most effective way of 
reducing the impact of stroke. 
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